Dupilumab: Eerste resultaten vanuit het BioDay-register

Lieneke F.M. Ariëns, J. van der Schaft, D. S. Bakker, D. M.W. Balak, B. Giovannone, M. Romeijn, T. Kouwenhoven, M. Kamsteeg, J. Drylewicz, F. van Wijk, S. Nierkens, J. L. Thijs, M. L. Schuttelaar, M. S. de Bruin-Weller

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

The effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis (AD) has been demonstrated in phase III clinical trials. At this moment, daily practice data on dupilumab treatment with respect to clinical effectiveness and safety are scarce. The objective of this study was to study the clinical effectiveness of 16 weeks treatment with dupilumab in adult patients with moderate to severe AD in daily practice. Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-weeks clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50, EASI-75 as well as patient reported outcome measures (POEM, DLQI, NRS-pruritus). A clinically relevant response was defined based on thresholds in one or more outcomes of the 3 major AD domains (EASI, NRS-pruritus, DLQI). In total, 138 patients treated with dupilumab in daily practice were included. This cohort included patients with very difficult- to-treat AD with 84 patients (61%) who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 was achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. Also patient-reported outcomes including sleep, itch and quality of life significantly improved during dupilumab treatment. A clinically relevant response was achieved by 89% of the patients after 16 weeks of treatment. The most reported side effects were conjunctivitis in 47 (34%) and eosinophilia in 78 (57%) patients. In conclusion, treatment with dupilumab significantly improved signs and symptoms of AD in patients with very difficult-to-treat AD in a daily practice setting with the majority of patients achieving a clinically relevant response after 16 weeks of treatment.

Vertaalde titel van de bijdrageDupilumab: Initial results from the BioDay registry
Originele taal-2Nederlands
Pagina's (van-tot)29-34
Aantal pagina's6
TijdschriftNederlands Tijdschrift voor Dermatologie en Venereologie
Volume29
Nummer van het tijdschrift4
StatusGepubliceerd - apr. 2019
Extern gepubliceerdJa

Trefwoorden

  • Atopic dermatitis
  • Biologic
  • Daily practice
  • Dupilumab

Vingerafdruk

Duik in de onderzoeksthema's van 'Dupilumab: Eerste resultaten vanuit het BioDay-register'. Samen vormen ze een unieke vingerafdruk.

Citeer dit